Paola Anselmo, Radiation Oncologist at S. Maria Hospital, Terni, shared a post on LinkedIn:
“Very interesting discussion of Pablo Muñoz Schuffenegger with an overview of oligometastatic NSCLC after an intriguing session ‘expanding horizon in Advanced NSCLC Integrating Local Therapy’ at WCLC25.
It is no longer possible to ignore the effectiveness and safety of SAbR in oncogene addicted and non oncogene addicted oligometastatic NSCLC.
Why not consider RT (SAbR) to the primary tumor?
New systemic therapy free survival.
Do you also agree with us that ‘new systemic-therapy free survival’ should be considered one of the primary end-points in clinical trials evaluating SAbR in oligoM NSCLC?”
